
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc has demonstrated strong growth in Chromium reaction volumes, indicating a robust market demand for its integrated solutions. Additionally, the company's consumables are projected to significantly outpace instrument revenue growth, with estimates suggesting an increase of 5-19 times by 2027 across its platforms. This combination of increased volumes and strong consumable sales expectations contributes to a positive outlook for the company's financial performance in the evolving life sciences market.
Bears say
10x Genomics has experienced a contraction in 2024, characterized by double-digit pricing pressure impacting revenues and resulting in flat to modestly lower volume sales. The company reported weaker-than-expected Q4 results, missing earnings per share estimates and projecting a full-year revenue outlook below expectations. Furthermore, despite expansion in certain market segments since its peak stock prices in 2021, the growth has not met analyst expectations, leading to a decline of over 90% in stock value during this period.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares